Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$0.66.

  • 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) rose 7739.73% to -$0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.28, marking a year-over-year increase of 9962.57%. This contributed to the annual value of -$18.55 for FY2024, which is 6866.32% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.66 for Q3 2025, which was up 7739.73% from -$1.18 recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $9.13 during Q3 2023, and registered a low of -$31.32 during Q4 2023.
  • Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$1.15 (2023), whereas its average is -$5.2.
  • Within the past 5 years, the most significant YoY rise in 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) was 159888.14% (2023), while the steepest drop was 437647.05% (2023).
  • Over the past 4 years, 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.7 in 2022, then tumbled by 4376.47% to -$31.32 in 2023, then skyrocketed by 84.69% to -$4.8 in 2024, then surged by 86.24% to -$0.66 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.66 in Q3 2025, compared to -$1.18 in Q2 2025 and -$1.56 in Q1 2025.